James Lancaster - Chief Executive Officer

James Y. Lancaster, Chief Executive Officer, is a seasoned entrepreneur and business development executive with 30 years of experience across multiple industries. He was most recently the Founder and Managing Director of the Innovate Family of Companies with client technologies including a variety of software, innovative materials, internet-of-things, robotics, autonomous vehicles, drone technologies, medical device, biological control, and waste recycling technologies. Prior to becoming an entrepreneur, he worked for Deloitte Consulting in Dallas with Fortune 500 and held other executive positions in business software and services, medical technologies, and IT solutions. He is currently the Managing Director of VIC Technology Venture Development’s Texas Branch.

David Greenberg, MD - Chief Medical Officer

David Greenberg is a co-inventor of the Solenic AMF technology. Dr. Greenberg completed his medical degree and residency at the Baylor College of Medicine, followed by fellowship training in infectious disease at the National Institutes of Health. His research interests stem from his time at the NIH, where he developed a passion for host-pathogen interactions, especially in the context of rare genetic diseases and immunocompromised hosts. As a clinically active Doctor on the Infectious Diseases (ID) consultation services at UTSW he is up-to-date on the current cases and concerns in the field and while overseeing and teaches fellows and residents.

Rajiv Chopra, PhD - Chief Technology Officer

Rajiv Chopra, PhD, Chief Technology Officer, is a co-inventor of the Solenic AMF technology. He completed his Bachelor’s degree in Physics at McMaster University in Hamilton, Ontario, and then completed his Ph.D. in Medical Biophysics at the University of Toronto. Dr. Chopra joined the Department of Radiology at UT Southwestern Medical Center to establish a new research program in image-guided therapy with a focus on HIFU. His research group is currently evaluating novel applications of MR-HIFU, with activities covering technology development, preclinical evaluation, and clinical trials.

Comments are closed.